argenx SE American Depositary Receipt (ARGX)
NASDAQ
Closed
Aug 21, 2026
Day's Range
1,029.4652 wk Range
658.60Overview - ARGX - argenx SE American Depositary Receipt
Key Statistics
Valuation
Enterprise Value
1.62T
P/E (Trailing)
‪39.68‬
P/E (Forward)
‪26.52‬
PEG Ratio
‪26.52‬
Price / Sales (TTM)
‪12.16‬
Price / Book
‪193.13‬
EV / EBITDA
‪1,004.71‬
Profitability
Gross Margin
‪90.42%‬
Profit Margin
‪32.26%‬
Operating Margin
‪31.99%‬
Return on Assets
‪11.63%‬
Return on Equity
‪23.63%‬
Ownership
Shares Outstanding
62.53M
Float
1.56B
Short % of Shares Outstanding
‪2.13%‬
Held by Insiders
‪0.00%‬
Held by Institutions
‪46.20%‬
Price stats
Beta
‪-0.04‬
50-Day Avg
‪894.64‬
200-Day Avg
‪836.54‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
1 analysts
Average price target
‪$ 1,172.78‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ARGX - argenx SE American Depositary Receipt
Peers - ARGX - argenx SE American Depositary Receipt
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ARGXNASDAQargenx SE American Depositary Receipt65.04BMarket Cap+34.86%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.60BMarket Cap-87.81%52-week change41.15P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE29.28BMarket Cap+9.87%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+24.84%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.93BMarket Cap+41.98%52-week change-21.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.16P/E (Trailing)‪2.14%‬Profit Margin
- ARWRNASDAQArrowhead Pharmaceuticals Inc.12.30BMarket Cap+76.22%52-week change47.10P/E (Trailing)‪-47.79%‬Profit Margin
Profile Summary - ARGX - argenx SE American Depositary Receipt
About
argenx SE is a global, commercial-stage biopharmaceutical company headquartered in Amsterdam, Netherlands, specializing in antibody-based therapies for severe autoimmune diseases. The company developed and commercializes VYVGART (efgartigimod), the first approved neonatal Fc receptor (FcRn) blocker, which is now…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
